This is a working overview of fatty diacid chain, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
Storage conditions for semaglutide depend heavily on the presentation. Lyophilized research powder is generally kept at two to eight degrees Celsius in a sealed container, protected from light and moisture. Manufacturer labeling for finished injectable products specifies refrigeration before first use, with defined in-use periods at room temperature afterward. The oral tablet form is stored at controlled room temperature and is more tolerant of short excursions. Temperature excursions should be documented rather than inferred.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
A non-Newtonian liquid is one where the viscosity is not independent of these factors and either thickens (increases in viscosity) or thins (decreases in viscosity) under shear. Examples of non-Newtonian liquids include ketchup, custard, or starch solutions.
== Horizontal gene transfer == Horizontal gene transfer (HGT) is the movement of genetic information between different organisms of the same species mainly being bacteria. This is not the movement of genetic information between a parent and their offspring but by other factors. In contrast to how animals reproduce and evolve from sexual reproduction, bacteria evolve by sharing DNA with other bacteria or their environment. There are three common mechanisms of transferring genetic material by HGT:
Distinguished as a biochemist. Was the first to show the possibility of using counter-current liquid-liquid extraction in the separation of N-acetylamino acids. In collaboration with A.J.P. Martin this led to the development of partition chromatography, which they have applied with conspicuous success in problems related to the composition and structure of proteins, particularly wool keratin. Synge's recent work on the composition and structure of gramicidins is outstanding and illustrates vividly the great advances in technique for which he and Martin are responsible. In 1963 he was elected a Fellow of the Royal Society of Edinburgh. His proposers were Magnus Pyke, Andrew Phillipson, Sir David Cuthbertson and John Andrew Crichton. He was for several years the treasurer of the Chemical Information Group of the Royal Society of Chemistry, and was an honorary Professor in Biological Sciences at the University of East Anglia from 1968 to 1984. He was awarded an honorary Doctor of Science (ScD) from the University of East Anglia in 1977, and an honorary doctorate from the Faculty of Mathematics and Science at Uppsala University, Sweden in 1980.
EMP, also known as estradiol normustine phosphate, is a combined estrogen ester and nitrogen mustard ester. It consists of estradiol, an estrogen, linked with a phosphate ester as well as an ester of normustine, a nitrogen mustard. In terms of its pharmacodynamic effects, EMP is a prodrug of estramustine, estromustine, and estradiol. As a prodrug of estradiol, EMP is an estrogen and hence an agonist of the estrogen receptors. EMP itself has only very weak affinity for the estrogen receptors. The medication is of about 91% higher molecular weight than estradiol due to the presence of its C3 normustine and C17β phosphate esters. Because EMP is a prodrug of estradiol, it may be considered to be a natural and bioidentical form of estrogen, although it does have additional cytostatic activity via estramustine and estromustine. EMP acts by a dual mechanism of action: 1) direct cytostatic activity via a number of actions; and 2) as a form of high-dose estrogen therapy via estrogen receptor-mediated antigonadotropic and functional antiandrogenic effects. The antigonadotropic and functional antiandrogenic effects of EMP consist of strong suppression of gonadal androgen production and hence circulating levels of androgens such as testosterone; greatly increased levels of sex hormone-binding globulin and hence a decreased fraction of free androgens in the circulation; and direct antiandrogenic actions in prostate cells. The free androgen index with oral EMP has been found to be on average 4.6-fold lower than with orchiectomy.
Sources: en.wikipedia.org
=== Physical properties === Compared to hydrogen in its natural composition on Earth, pure deuterium (2H2) has a higher melting point (18.72 K vs. 13.99 K), a higher boiling point (23.64 vs. 20.27 K), a higher critical temperature (38.3 vs. 32.94 K) and a higher critical pressure (1.6496 vs. 1.2858 MPa). The physical properties of deuterium compounds can exhibit significant kinetic isotope effects and other physical and chemical property differences from the protium analogs. 2H2O, for example, is more viscous than normal H2O. There are differences in bond energy and length for compounds of heavy hydrogen isotopes compared to protium, which are larger than the isotopic differences in any other element. Bonds involving deuterium and tritium are somewhat stronger than the corresponding bonds in protium, and these differences are enough to cause significant changes in biological reactions. Pharmaceutical firms are interested in the fact that 2H is harder to remove from carbon than 1H. Deuterium can replace 1H in water molecules to form heavy water (2H2O), which is about 10.6% denser than normal water (so that ice made from it sinks in normal water). Heavy water is slightly toxic in eukaryotic animals, with 25% substitution of the body water causing cell division problems and sterility, and 50% substitution causing death by cytotoxic syndrome (bone marrow failure and gastrointestinal lining failure). Prokaryotic organisms, however, can survive and grow in pure heavy water, though they develop slowly.
The company was co-founded in 1988 by Donald and Susan Sutherland, who sought ice cream that was neither hard packed nor soft-serve. Cold Stone Creamery opened its first store that year in Tempe, Arizona. The original Cold Stone Creamery, store #0001, remains in operation near the same intersection at the southwest corner of McClintock and Southern in Tempe. The store moved from the original location to this location in the early 1990s. The company has maintained the same concept created by Steve Herrell, who founded Steve's Ice Cream. Patrons select a flavor of ice cream and then choose a number of mix-ins to be added to the ice cream. Mix-ins include candies, nuts, brownies and syrups. Cold Stone derives its name from the frozen granite slab that employees use to fold mix-ins into the ice cream. In 1995, Cold Stone Creamery opened its first franchise store in Tempe, Arizona. Shortly after, a second location was opened, in Camarillo, California. Cold Stone Creamery has become the sixth best-selling brand of ice cream in the US. In 2008, Cold Stone opened its first European franchise in Copenhagen, Denmark. Three more stores were later opened in other parts of the country. In January 2006, the company was named the 11th fastest-growing franchise by Entrepreneur magazine. In June 2009, the company opened its first locations in Canada. As of 2012, three stores had opened in Singapore. In 2012, Cold Stone opened its first store in Nigeria, the first in Sub-Saharan Africa.
Oxycodone was first made available in the United States in 1939. In the 1970s, the FDA classified oxycodone as a Schedule II drug, indicating a high potential for non-medical use and addiction. After its 1995 approval by the FDA by Deputy Director Curtis Wright IV, Purdue Pharma introduced OxyContin, a controlled release formulation of oxycodone in 1996. However, drug users quickly learned how to simply crush the controlled release tablet to swallow, inhale, or inject the high-strength opioid for a powerful morphine-like high. In fact, Purdue's private testing conducted in 1995 determined that 68% of the oxycodone could be extracted from an OxyContin tablet when crushed. In 2007, Purdue paid $600 million in fines after being prosecuted for making false claims about the risk of opioid use disorder associated with oxycodone. In 2010, Purdue Pharma reformulated OxyContin, using a polymer to make the pills extremely difficult to crush or dissolve in water to reduce non-medical use of OxyContin. The FDA approved relabeling the reformulated version as abuse-resistant. OxyContin use following the 2010 reformulation declined slightly while no changes were observed in the use of other opioids. In June 2017, the FDA asked the manufacturer to remove its long-acting form of oxymorphone (Opana ER) from the US market, because the drug's benefits may no longer outweigh its risks, this being the first time the agency has asked to remove a currently marketed opioid pain medication from sale due to public health consequences of non-medical use.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Sealed, protected from light, and refrigerated at two to eight degrees Celsius for most research material. Desiccated storage limits moisture uptake. Allow the vial to reach room temperature before opening to prevent condensation.